A Republican accelerated approval reform proposal attempts to expand eligibility for the US Food and Drug Administration’s expedited pathway and eschews automatic expiration dates for product clearances.
Current law states that the FDA can approve a product using the pathway upon a determination of an effect on...
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?







